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To the Editor—Yau et al1 report that, in Hong Kong, 
over 25% of breast cancer cases showing HER2 
overexpression on immunohistochemistry cannot 
be verified by in-situ hybridisation (ISH) assays. The 
implication is that ISH should always be performed if 
anti-HER2 drug therapy is contemplated.
 Our results, from tests performed at Queen 
Elizabeth Hospital, Hong Kong, are different. Of 260 
consecutive invasive breast cancers, 57.3% scored 0 or 
1 (negative) on HER2 immunostaining , 26.2% scored 
2 (borderline) and 16.5% scored 3 (strong), results 
comparable to those reported in the literature.2 Our 
correlation study using the fluorescence ISH test 
for HER2 amplification (PathVysion Kit) shows HER2 
amplification in none of the 10 negative cases (score 
0 or 1), four (6.9%) of 58 score 2 cases, and 12 (92.3%) 
of 13 score 3 cases. The single negative score 3 case 
showed increased copies of HER2 gene, but since 
there was also chromosome 17 polysomy, the ratio 
of HER2/CEP17 fell below 2.2 (negative by definition). 
The good concordance between strong HER2 
overexpression with HER2 amplification supports the 
general recommendation that breast cancers with 
score 3 HER2 overexpression do not require molecular 
confirmation. The differences between our results 
and those reported by Yau et al may be due to their 
inclusion of results from different laboratories, using 
different antibodies and different technologies.
 Finally, we doubt the latest guidelines for 
score 3 positivity (30% instead of 10% tumour 
cells exhibiting strong circumferential membrane 
staining3) will improve accuracy and concordance. 
In our experience, the percentage of positive cells is 
never an issue where there is strong, thick membrane 
staining because this is almost always seen in 
practically all tumour cells (Fig).
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FIG. Invasive breast carcinoma showing strong overexpression 
of HER2 (score 3) on immunostaining
Note that practically every tumour cell exhibits circumferential, 
thick cell membrane staining
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To the Editor—We thank Dr Chan and his colleagues 
for their interest in our paper. The most critical point 
in this discussion is the need for accurate HER2 
tests from all laboratories because the results have 
such profound clinical implications. High HER2 test 
accuracy can indeed be achieved in high-volume 
laboratories but extrapolating their results to other 
laboratories can be misleading. Our study, analysing 
private and public laboratory results, reflects the real 
world situation in Hong Kong. Another local series, 
studying 1485 Chinese women, also found a relatively 
high HER2 overexpression rate (22-28% in different 
age-groups).1
 Dr Chan et al’s experience of a high percentage 
of tumour cells showing strong staining in true 
immunohistochemistry (IHC) 3+ cases is well 
recognised. The international guidelines2 state “a 
cutoff of more than 30% reflects the cumulative 
experience of panel members that usually a high 
percentage of the cells will be positive if it is a true 
IHC 3+, published reports using cutoff values higher 
than 10%,3 and the goal of the panel to decrease the 
incidence of false-positive 3+”. Preliminary evidence 
suggests the revised cutoff of 30% may help improve 
the accuracy of poorer-performing laboratories.4
 We advocate compliance with the latest 
international guidelines2 to improve the accuracy of 
HER2 testing. They clearly state that there is no need 
to repeat ISH testing for IHC 3+ cases and validated 
ISH tests should be performed for equivocal (IHC 
2+) cases. Some IHC 3+ cases diagnosed using 
the original 10% cutoff would now be considered 
equivocal (2+) and hence validated ISH confirmation 
tests may be considered before commencement of 
anti-HER2 therapy, unless the laboratory can provide 
supporting information. 
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